Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jacques Cadranel

Showing results (231-240 of 329) with videos related to

Pageof 33
Sort By:
The European Respiratory Journal|February 16, 2018
Immunotherapy: a new standard of care in thoracic malignancies? A summary of the European Respiratory Society research seminar of the Thoracic Oncology AssemblyAdrien Costantini, Marta Grynovska, Francesca Lucibello, et al.
Pharmaceutics|September 23, 2022
Exposure-Response Analysis of Osimertinib in Patients with Advanced Non-Small-Cell Lung CancerThomas Rodier, Alicja Puszkiel, Evelina Cardoso, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 28, 2018
c-MET Overexpression as a Poor Predictor of MET Amplifications or Exon 14 Mutations in Lung Sarcomatoid CarcinomasXavier Mignard, Anne-Marie Ruppert, Martine Antoine, et al.
Cancers|April 12, 2022
Brigatinib for Pretreated, ALK-Positive, Advanced Non-Small-Cell Lung Cancers: Long-Term Follow-Up and Focus on Post-Brigatinib Lorlatinib Efficacy in the Multicenter, Real-World BrigALK2 StudyRenaud Descourt, Maurice Pérol, Gaëlle Rousseau-Bussac, et al.
EMBO Molecular Medicine|December 23, 2016
The RAS-related GTPase RHOB confers resistance to EGFR-tyrosine kinase inhibitors in non-small-cell lung cancer via an AKT-dependent mechanismOlivier Calvayrac, Julien Mazières, Sarah Figarol, et al.
The European Respiratory Journal|May 30, 2015
Heterozygous RTEL1 mutations are associated with familial pulmonary fibrosisCaroline Kannengiesser, Raphael Borie, Christelle Ménard, et al.
Thrombosis and Haemostasis|September 22, 2020
Derivation and Validation of a Predictive Score for Disease Worsening in Patients with COVID-19Grigoris T Gerotziafas, Theodoros N Sergentanis, Guillaume Voiriot, et al.
Critical Care (London, England)|May 20, 2020
Severe diffuse alveolar hemorrhage related to autoimmune disease: a multicenter studyAdrien Mirouse, Antoine Parrot, Vincent Audigier, et al.
Lung Cancer (Amsterdam, Netherlands)|October 11, 2019
Resistance mechanisms to osimertinib in EGFR-mutated advanced non-small-cell lung cancer: A multicentric retrospective French studyCamille Mehlman, Jacques Cadranel, Gaelle Rousseau-Bussac, et al.
The Oncologist|December 26, 2024
COMPOSIT study: evaluating osimertinib combination with targeted therapies in EGFR-mutated non-small cell lung cancerCamille Mehlman, Aurelie Swalduz, Isabelle Monnet, et al.
Pageof 33

Showing results (231-240 of 329) with videos related to

Sort By:
Pageof 33
The European Respiratory Journal|February 16, 2018
Immunotherapy: a new standard of care in thoracic malignancies? A summary of the European Respiratory Society research seminar of the Thoracic Oncology AssemblyAdrien Costantini, Marta Grynovska, Francesca Lucibello, et al.
Pharmaceutics|September 23, 2022
Exposure-Response Analysis of Osimertinib in Patients with Advanced Non-Small-Cell Lung CancerThomas Rodier, Alicja Puszkiel, Evelina Cardoso, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 28, 2018
c-MET Overexpression as a Poor Predictor of MET Amplifications or Exon 14 Mutations in Lung Sarcomatoid CarcinomasXavier Mignard, Anne-Marie Ruppert, Martine Antoine, et al.
Cancers|April 12, 2022
Brigatinib for Pretreated, ALK-Positive, Advanced Non-Small-Cell Lung Cancers: Long-Term Follow-Up and Focus on Post-Brigatinib Lorlatinib Efficacy in the Multicenter, Real-World BrigALK2 StudyRenaud Descourt, Maurice Pérol, Gaëlle Rousseau-Bussac, et al.
EMBO Molecular Medicine|December 23, 2016
The RAS-related GTPase RHOB confers resistance to EGFR-tyrosine kinase inhibitors in non-small-cell lung cancer via an AKT-dependent mechanismOlivier Calvayrac, Julien Mazières, Sarah Figarol, et al.
The European Respiratory Journal|May 30, 2015
Heterozygous RTEL1 mutations are associated with familial pulmonary fibrosisCaroline Kannengiesser, Raphael Borie, Christelle Ménard, et al.
Thrombosis and Haemostasis|September 22, 2020
Derivation and Validation of a Predictive Score for Disease Worsening in Patients with COVID-19Grigoris T Gerotziafas, Theodoros N Sergentanis, Guillaume Voiriot, et al.
Critical Care (London, England)|May 20, 2020
Severe diffuse alveolar hemorrhage related to autoimmune disease: a multicenter studyAdrien Mirouse, Antoine Parrot, Vincent Audigier, et al.
Lung Cancer (Amsterdam, Netherlands)|October 11, 2019
Resistance mechanisms to osimertinib in EGFR-mutated advanced non-small-cell lung cancer: A multicentric retrospective French studyCamille Mehlman, Jacques Cadranel, Gaelle Rousseau-Bussac, et al.
The Oncologist|December 26, 2024
COMPOSIT study: evaluating osimertinib combination with targeted therapies in EGFR-mutated non-small cell lung cancerCamille Mehlman, Aurelie Swalduz, Isabelle Monnet, et al.
Pageof 33